A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
A phase 3 trial of Zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Leucovorin (folinic acid) and Fluorouracil (5-FU) in gastric & gastro-oesophageal junction cancer, run by Astellas Pharma Global Development, Inc., now recruiting.
Overview
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer is a phase 3 interventional study registered as NCT06901531 by Astellas Pharma Global Development, Inc., with 500 participants planned, started 2025-05-22 and due to reach its primary completion in 2028-09-30. Interventions recorded: zolbetuximab, Pembrolizumab, Capecitabine, Oxaliplatin, Folinic acid (leucovorin or local equivalent) and 5-fluorouracil (5-FU).
Similar pages
not linked directly; found by shared links- TrialA Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Shares Zolbetuximab, Astellas, Oxaliplatin, Capecitabine and the tag pipeline.
- TrialA Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
Shares Zolbetuximab, Leucovorin (folinic acid), Astellas, Oxaliplatin and the tag pipeline.
- TrialEvaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.
- TrialSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Shares Zolbetuximab, Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Shares Astellas, Oxaliplatin, Pembrolizumab and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Fluorouracil (5-FU), Oxaliplatin, Capecitabine, Gastric & gastro-oesophageal junction cancer and the tag pipeline.